-
公开(公告)号：US20240342245A1
公开(公告)日：2024-10-17
申请号：US18681726
申请日：2022-08-05
发明人： Yoshimasa TANAKA , Kiminori KIMURA
IPC分类号： A61K38/20 , A61K39/395 , A61P35/00
CPC分类号： A61K38/20 , A61K38/2013 , A61K38/2046 , A61K38/2086 , A61K39/3955 , A61P35/00
摘要： The present invention provides novel and effective cancer immunotherapeutic agents that exhibit therapeutic effects on intractable cancers, particularly cancers for which immune checkpoint inhibitor(s) monotherapy or combined use thereof with other drug(s) is ineffective. Specifically, a cancer therapeutic agent containing an immune checkpoint inhibitor, interleukin-18 (IL-18), and a T cell growth factor (e.g., interleukin-2 (IL-2)) in combination is provided.
-
公开(公告)号：US20240335512A1
公开(公告)日：2024-10-10
申请号：US18746283
申请日：2024-06-18
CPC分类号： A61K38/2046 , A61K38/19 , A61P35/00 , A61P35/02 , G01N33/57426 , G01N33/57492 , A61K38/1808 , A61K45/06 , G01N33/57411 , G01N33/57423 , G01N33/57449
摘要： In one aspect, methods of treating a subject having a cancer that expresses a cytokine receptor are provided. In some embodiments, the method comprises administering to the subject a biologic agent in an amount sufficient to induce loss of cytokine receptor signaling through increased expression of a Suppressor of Cytokine Signaling genes and/or loss of one or more cytokine receptor components from the cancer cell surface. In some embodiments, the biologic agent is a cytokine or cytokine mimetic.
-
公开(公告)号：US20240165207A1
公开(公告)日：2024-05-23
申请号：US18283589
申请日：2022-03-25
发明人： Incheol RYU , Daeun JEONG , Sihyeon AN , Seong Heon KIM , Yunseon KIM , Kanghyun RYOO , Hyunseung LEE , Dong-Oh YOON , Myoungwoo LEE , Misun WON , Joo-Young IM
CPC分类号： A61K38/44 , A61K38/193 , A61K38/20 , A61K38/2013 , A61K38/2046 , A61K38/208 , A61K38/2086 , A61P35/00 , C12Y106/02002
摘要： The present invention relates to a composition for preventing or treating cancer, comprising a dual expression vector, and more specifically, to a method for effectively treating cancer by simultaneously inducing the actions of cancer metabolism drugs and cancer immunotherapy drugs by using a dual expression vector for simultaneously expressing an HIF-1α inhibitor and anticancer cytokines.
-
公开(公告)号：US20230398184A1
公开(公告)日：2023-12-14
申请号：US18250660
申请日：2021-10-25
发明人： Donghoon CHOI , Young Chul SUNG , Seung-Woo LEE , Sora KIM , Young-Min KIM
IPC分类号： A61K38/20 , A61K35/28 , A61K38/19 , A61K31/395
CPC分类号： A61K38/2046 , A61K35/28 , A61K38/193 , A61K31/395
摘要： The present disclosure relates to methods of promoting the mobilization of HSCs to the peripheral blood with an IL-7 protein. In some aspects, the method further comprises administering an additional agent, such as G-CSF and/or AMD3100. In some aspects, the methods disclosed herein are useful in treating a disease or disorder associated with an abnormality of a hematopoietic process.
-
5.发明公开公开(公告)号：US20230364218A1
公开(公告)日：2023-11-16
申请号：US18361084
申请日：2023-07-28
申请人： Etubics Corporation
IPC分类号： A61K39/12 , A61K39/21 , C12N15/86 , A61K39/00 , A61P35/00 , A61K38/19 , A61K38/20 , A61K38/21 , A61K39/235 , C07K14/005 , C07K14/705 , C07K14/71
CPC分类号： A61K39/12 , A61K39/21 , C12N15/86 , A61K39/00 , A61P35/00 , A61K39/001106 , A61K39/001182 , A61K38/191 , A61K38/193 , A61K38/2013 , A61K38/2026 , A61K38/2033 , A61K38/204 , A61K38/2046 , A61K38/2066 , A61K38/208 , A61K38/217 , A61K39/235 , A61K39/0011 , C07K14/005 , C07K14/70503 , C07K14/71 , A61K2039/5256 , C12N2710/10343 , A61K2039/545 , C12N2740/16234 , C12N2710/10334 , C12N2710/10034 , A61K2039/54 , A61K2039/55555 , A61K2039/575 , C12N2710/10321 , C12N2710/20034 , C12N2740/15034 , C12N2800/24 , A61K2039/57 , C12N2710/10371
摘要： Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided.
-
公开(公告)号：US20230285559A1
公开(公告)日：2023-09-14
申请号：US18015709
申请日：2021-07-22
发明人： Zhen Gu , Quanyin Hu , Hongjun Li
CPC分类号： A61K39/4631 , A61K9/06 , A61K47/6901 , A61K47/6843 , A61K39/4611 , A61K47/36 , A61K38/2086 , A61K38/2046 , A61P35/00
摘要： A therapeutic hydrogel material is disclosed for the delivery of CAR-T cells that allows their distribution in the tumor resection recess, cavity, or void in combination with platelets decorated with the anti-programmed death-ligand 1 (PDL1) blocking antibody (aPDL1). The delivered hydrogel material acts as a reservoir for both CAR-T cells and platelet-bound aPDL1. Furthermore, inflammation occurring during the surgical wound healing triggers the release of platelet-derived microparticles containing the aPDL1. Cells delivered by the engineered hydrogel show significant control of local and distant tumor recurrence without causing toxic effects. In some embodiments, nanoparticles containing cytokines are also loaded in the therapeutic hydrogel material to maintain the activity and proliferation ability of CAR-T cells.
-
公开(公告)号：US20230285513A1
公开(公告)日：2023-09-14
申请号：US18064793
申请日：2022-12-12
IPC分类号： A61K38/22 , A61K45/06 , A61K31/44 , A61K31/165 , C07K16/28 , A61K39/395 , A61K31/655 , A61K38/19 , A61K38/20 , A61K38/21 , A61P35/00 , A61P35/04
CPC分类号： A61K38/2292 , A61K45/06 , A61K31/44 , A61K31/165 , C07K16/2818 , A61K39/39558 , A61K31/655 , A61K38/193 , A61K38/2046 , A61K38/21 , A61P35/00 , A61P35/04 , C07K2317/70
摘要： The present invention provides compositions and methods for treating cancer or a metastasis thereof in a subject. In some embodiments, the methods involve administering a composition comprising therapeutically effective amount of at least one immune stimulator to the subject. In some embodiments, a combination of at least two immune stimulators is used for the treatment. In some embodiments, the combination includes an alpha thymosin peptide and an additional immune stimulator, and/or optionally one or more additional anti-cancer agents.
-
公开(公告)号：US11708399B2
公开(公告)日：2023-07-25
申请号：US15775182
申请日：2016-12-02
申请人： GENEXINE, INC.
CPC分类号： C07K14/5418 , A61K9/0034 , A61K9/08 , A61K38/2046 , A61K47/02 , A61P35/00 , C07K2319/30
摘要： The present invention relates to a pharmaceutical composition comprising an immunoglobulin Fc region and an IL-7 fusion protein. Specifically, when a fusion protein comprising the immunoglobulin Fc region and IL-7 is administered to an affected area, a strong immune response is induced in the body and thus allows human papillomavirus-caused diseases to be prevented or treated.
-
公开(公告)号：US20180161399A1
公开(公告)日：2018-06-14
申请号：US15641550
申请日：2017-07-05
IPC分类号： A61K38/22 , A61K38/21 , A61K38/20 , A61K45/06 , A61K31/44 , A61K38/19 , C07K16/28 , A61K39/395 , A61K31/655 , A61K31/165
CPC分类号： A61K38/2292 , A61K31/165 , A61K31/44 , A61K31/655 , A61K38/193 , A61K38/2046 , A61K38/21 , A61K39/39558 , A61K45/06 , A61P35/00 , A61P35/04 , C07K16/2818 , C07K2317/70 , A61K2300/00
摘要： The present invention provides compositions and methods for treating cancer or a metastasis thereof in a subject. In some embodiments, the methods involve administering a composition comprising therapeutically effective amount of at least one immune stimulator to the subject. In some embodiments, a combination of at least two immune stimulators is used for the treatment. In some embodiments, the combination includes an alpha thymosin peptide and an additional immune stimulator, and/or optionally one or more additional anti-cancer agents.
-
10.发明申请公开(公告)号：US20170173135A1
公开(公告)日：2017-06-22
申请号：US15447598
申请日：2017-03-02
申请人： Immunotope, Inc.
发明人： Ramila Philip
CPC分类号： A61K39/0011 , A61K38/191 , A61K38/193 , A61K38/2006 , A61K38/2013 , A61K38/2046 , A61K38/208 , A61K38/2086 , A61K2039/55566 , A61K2039/572 , C07K7/06 , C07K14/4748 , C07K14/70539
摘要： The present invention relates to compositions and methods for the prevention, treatment, and diagnosis of cancer, especially carcinomas, such as pancreatic carcinoma. The invention discloses peptides, polypeptides, and polynucleotides that can be used to stimulate a CTL response against pancreatic and other cancers.
-
-
-
-
-
-
-
-
-
搜索结果
186 条记录 (耗时 0.03 秒)
